Lv3
320 积分 2025-11-23 加入
Circulating tumor DNA in early-stage NSCLC: prognostic value and challenges
3天前
已完结
Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy
4天前
已完结
Liquid biopsy: Comprehensive overview of circulating tumor DNA (Review)
7天前
已完结
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer
1个月前
已完结
P3.13.34 Tarlatamab Efficacy and Safety in Chinese Patients with Advanced Small Cell Lung Cancer: Phase 2 DeLLphi-307
1个月前
已关闭
Minimal residual disease as a target for liquid biopsy in patients with solid tumors
2个月前
已完结
Adjuvant therapy-free strategy for stage IB to IIIA non-small-cell lung cancer patients after radical resection based on longitudinal undetectable molecular residual disease: prospective, multicenter, single-arm study
2个月前
已完结
皖公网安备34019202002308
